sleepinglizard
Joined: 27 Dec 2004
Posts: 1037
|
 Posted: April 25 2007 Post subject: New drug in clinical trials |
 |
|
There is a new drug in clinical trials for CRD.
| Quote: | VEC-162 (phase II/III)
VEC-162 is a melatonin agonist under development for the treatment of sleep disorders (insomnia, circadian rhythm sleep disorders) and mood disorders (including depression). Vanda licensed VEC-162 from Bristol-Myers Squibb Company in 2004. Vanda has completed phase II for VEC-162 in insomnia and has initiated a phase III trial.
In addition to these compounds, Vanda has acquired and/or is evaluating other candidates for clinical development.
http://www.vandapharmaceuticals.com/development.html
|
|
|
FAQ
Register
Profile 
Log in 
